Trials / Withdrawn
WithdrawnNCT01882712
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily for 29 days versus vehicle control, in subjects with moderate to severe chronic persistent vascular facial erythema
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD07805/47 Gel 0.5% | |
| DRUG | CD07805/47 Gel Placebo |
Timeline
- Primary completion
- 2015-09-01
- First posted
- 2013-06-20
- Last updated
- 2014-11-06
Source: ClinicalTrials.gov record NCT01882712. Inclusion in this directory is not an endorsement.